Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised the arrangers in connection with Heimstaden’s EUR 350,000,000 bond issuance
Mandate

Vinge has advised the arrangers in connection with Heimstaden’s EUR 350,000,000 bond issuance

March 09, 2021 Banking and Finance Capital Markets and Public M&A

The banks acted as arrangers and bookrunners in connection with Heimstaden AB’s (publ) issuance of EUR 350,000,000 senior unsecured bonds, within a framework amount of EUR 450,000,000.

The bond proceeds are intended to be used for the purchase of equity in Heimstaden Bostad AB and general corporate purposes. In accordance with the terms and conditions, the bonds are intended to be listed on the corporate bond list of Nasdaq Stockholm.

Vinge’s team consisted of Louise Brorsson Salomon and Lionardo Ojeda (Banking and Finance) together with Jesper Schönbeck and Linnéa Sellström (Capital Markets and Public M&A).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026